NR3C2 and Hyperkalemia: The medications that were more frequently found in patients with hyperkalemia than the control group in this study were RAASi (29.0%, vs. 15.4%), including angiotensin receptor blocker (ARB, 17.6% vs. 10.7%) and mineralocorticoid receptor antagonist (MRA, 9.92% vs. 2.01%) (Table 1).